Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

ExonHit unveils new SpliceArray tool for disease modelling

ExonHit Therapeutics : 07 May, 2008  (New Product)
ExonHit Therapeutics has introduced its new SpliceArray for use in disease modelling and toxicogenomic applications by the basic and pre-clinical research communities.
The SpliceArray products provide the highest resolution expression profiling analysis for the rat genome commercially available today. ExonHit's patented approach to detect all known and novel expressed transcripts is now offered through our portfolio of genomic services.

The Rat SpliceArray monitors over 23,000 genes utilising more than 200,000 exon body and 180,000 splice junction regions. The comprehensive coverage enables investigators to further elucidate the diversity of the rat transcriptome. The new designs, manufactured on the Agilent Technologies and Affymetrix Microarray platforms, now expand the company’s product offering and enable researchers to make use of alternative splicing discovery in the rat model system.

'ExonHit continues to grow its catalogue of arrays for it genomics services. This most recent addition will expand our ability to service clients who use rat models in elucidating disease biology, as well as for ExonHit's discovery collaboration programmes for therapeutic targets and safety biomarkers,' said John R Jaskowiak, executive vice president of molecular diagnostics and genomics services at ExonHit Therapeutics.

'The addition of this model organism to the SpliceArray product family further expands our presence in the expression profiling market. We strongly believe that these new SpliceArray products will further accelerate the understanding of mechanism of actions and ultimately the discovery of new therapeutics while providing unprecedented toxicogenomics data,' stated Philippe Rousseau, chairman of the executive board of ExonHit Therapeutics. 'Additionally, recent peer-reviewed publications in Cancer Research and Proceedings of the National Academy of Sciences further validate our high resolution approach to expression profiling.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo